Back

Myeloperoxidase promotes fibrosis by inhibiting cathepsin K to bias the lung toward ECM accumulation

Link, P. A.; Wellmerling, J. H.; Meridew, J. A.; Naoi, H.; Prakash, Y.; Rojas, M.; Carmona, E. M.; Tschumperlin, D. J.

2026-04-07 pathology
10.64898/2026.04.05.713467 bioRxiv
Show abstract

Pulmonary fibrosis (PF) involves excessive collagen accumulation, yet mechanisms shifting the balance of synthesis and degradation toward net deposition remain unclear. Myeloperoxidase (MPO) inversely correlates with survival in PF. Using the bleomycin model, we found MPO knockout (MPOko) mice were protected from fibrosis, and pharmacological MPO inhibition after peak inflammation (day 7) recapitulated this protection. MPO persisted in lung tissue 21 days post-injury despite neutrophil efflux, linking acute inflammation to sustained remodeling. Mechanistically, we identified that MPO inhibits Cathepsin K (CatK), a potent collagenolytic enzyme involved in fibrosis resolution. Notably, CatK gene expression (CTSK) is elevated in PF, suggesting post-translational inhibition of CatK. MPOko and inhibitor-treated mice exhibited elevated CatK activity after bleomycin; exogenous addition of pathophysiologic concentrations of MPO reduced CatK activity in mouse precision-cut lung slices and human fibroblasts. Biochemically, MPO reduced CatK activity to 33% of control. In two distinct cohorts of PF patients, we observed significantly increased MPO protein levels in platelet poor plasma and in lung tissue. In PF patients, 62% had MPO levels in platelet poor plasma exceeding healthy controls, while lung tissue from other PF patients showed significantly elevated MPO staining. Plasma levels were inversely correlated with decreased survival, FVC, and DLCO. These findings establish MPO as a post-translational inhibitor of CatK-mediated collagenolysis, revealing a mechanism linking acute inflammation to sustained fibrosis and suggest a patient subpopulation that may benefit from MPO-targeted therapy. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=54 SRC="FIGDIR/small/713467v1_ufig1.gif" ALT="Figure 1"> View larger version (17K): org.highwire.dtl.DTLVardef@d8fc5eorg.highwire.dtl.DTLVardef@1a088fcorg.highwire.dtl.DTLVardef@818b7dorg.highwire.dtl.DTLVardef@ecdca0_HPS_FORMAT_FIGEXP M_FIG C_FIG Myeloperoxidase persists in lung tissue after injury and inhibits cathepsin K activity, impairing collagen degradation and promoting extracellular matrix accumulation during pulmonary fibrosis.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
JCI Insight
241 papers in training set
Top 0.1%
18.2%
2
Nature Communications
4913 papers in training set
Top 19%
9.9%
3
American Journal of Respiratory Cell and Molecular Biology
38 papers in training set
Top 0.1%
8.2%
4
Journal of Clinical Investigation
164 papers in training set
Top 0.4%
6.2%
5
Cell Reports
1338 papers in training set
Top 8%
6.2%
6
American Journal of Respiratory and Critical Care Medicine
39 papers in training set
Top 0.1%
6.2%
50% of probability mass above
7
Cell Stem Cell
57 papers in training set
Top 0.3%
4.8%
8
Science Translational Medicine
111 papers in training set
Top 0.6%
4.2%
9
European Respiratory Journal
54 papers in training set
Top 0.5%
3.5%
10
eLife
5422 papers in training set
Top 27%
3.5%
11
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 31%
1.7%
12
EBioMedicine
39 papers in training set
Top 0.4%
1.6%
13
Circulation
66 papers in training set
Top 2%
1.3%
14
Molecular Therapy
71 papers in training set
Top 2%
1.2%
15
Advanced Science
249 papers in training set
Top 15%
1.1%
16
Arteriosclerosis, Thrombosis, and Vascular Biology
65 papers in training set
Top 2%
0.9%
17
Blood
67 papers in training set
Top 1%
0.7%
18
Acta Biomaterialia
85 papers in training set
Top 0.9%
0.7%
19
Modern Pathology
21 papers in training set
Top 0.5%
0.7%
20
Circulation Research
39 papers in training set
Top 1%
0.7%
21
Brain
154 papers in training set
Top 5%
0.7%
22
The EMBO Journal
267 papers in training set
Top 6%
0.7%
23
Cell Reports Medicine
140 papers in training set
Top 9%
0.7%
24
The FASEB Journal
175 papers in training set
Top 4%
0.6%
25
EMBO Molecular Medicine
85 papers in training set
Top 6%
0.6%
26
Science Advances
1098 papers in training set
Top 33%
0.6%